Analysis of plasma phenytoin in a group of patients treated for epilepsy showed that only 36 %had values in the therapeutic range. The relationship between plasma phenytoin, body weight, and daily dosage of the drug were explored, and the data were analysed by multiple regression. The resultant equation, relating all three factors, was used to optimise drug dosage, and the importance of using the body weight of the patient before starting a phenytoin regimen is emphasised. An increase in the number of patients with plasma phenytoin in the therapeutic range was achieved, and the clinical value of being in that range is shown.
Phenytoin is widely used in the treatment of epilepsy, and before analysis of its concentration in the blood became available the regime recommended in standard texts-was to increase the dose until symptoms of overdosage occurred and then to cut back the dose slightly, the so-called titration method. This approach can lead to difficulties with phenytoin because the plasma concentration is not linearly related to the dose, and a small incremental increase in drug intake may give rise to a disproportionate rise in the blood. The explanation for this phenomenon is that the drug quickly saturates the hepatic microsomal oxidation system and thus follows zeroorder kinetics.s The pharmacokinetic behaviour of a drug can be a useful guide to developing a dosage regime.P and Richens and Dunlop-have devised a nomogram to calculate the required dosage of phenytoin once an accurate blood concentration is known. This measure was based on the observed kinetic behaviour of phenytoin in a small group of patients and has proved to be very useful. Pippenger? emphasised that modification of dosage regimes to take into account patient weights resulted in a significant improvement in the number of patients who are maintained in the optimal therapeutic range. In our experience, it was noticeable that very different dosage regimens were required in people of different size, and this possible relationship was explored in an attempt to provide a basis for phenytoin administration.
for treatment of epilepsy for periods ranging from two months to four years. The reasons for drug analysis were given as 'check on long-term dosage', 'fits despite treatment', 'toxic fits', and some (approximately 20%) were suspected of noncompliance. The majority of these patients were on multiple drug therapy, but some were not, and this latter group was used to calculate the relationship between body weight, daily dosage, and plasma phenytoin concentration (n = 136).
The proportion of the group on phenytoin alone who were recorded as having 'fits' was also noted, and a subgroup was used to illustrate the effect of modifying the dosage regime.
METHODS
Phenytoin was measured by HPLC (model Sigma 3, Perkin-Elmer, Beaconsfield, England) using the method of Adams and Vandermark" but modifying the acetonitrile concentration to 40 % in water, to speed the elution, and reading the eluted phenytoin at 225 nm.
STATISTICS
Statistical methods were taken from Colquhoun," and the calculation of multiple linear regression from the data was made using the programme provided for this analysis by Hewlett Packard for use with the 9815A desk-top calculator.
Results

Patients and methods
The proportions of all values lying above, within, PATIENTS and below the therapeutic range for phenytoin were All the patients investigated had been on phenytoin calculated, and the percentages are shown in Table 1 . 141
Blood concentrations above the range may be associated with toxic symptoms, while values below the range may be evidence of underdosage. 
Plasma phenytoin
Of the 608 values, all but 136 were on multiple drug therapies. Some of these were anti-convulsants, but many were not, and their interactions with the blood concentrations of phenytoin were unknown. When plasma phenytoin concentrations were plotted against the total daily dose of the drug a curvilinear relationship was discernible ( Figure 1 ). Within the group of patients were some who had been on several changes of drug dosage, and when their results were plotted, several smooth curves were obtained which implied that the data in Fig. 1 were comprised of a family of lines belonging to patients of different metabolic behaviour.
The relationship between plasma phenytoin and the individual's weight on a given daily dose of the drug was explored, and the results are illustrated in Figure 2 . A curvilinear plot with a negative slope resulted, which could best be fitted by a single exponential term indicative of single-compartment distribution of the drug. Thus the plot of Fig. 1 relating plasma levels and dosage is composed of at least two components: one with a positive slope describing the zero-order kinetics in the plasma and the second with a negative slope reflecting the effect of differing body sizes. 200 50
Phenytcin dose
Therapeutic range 40  45  50  55  60  65  70  75  80  85  90  95  100  Calculated dose  (mg/day)  218  235  252  271  288  306  323  341  358  376  393  411  429  Recommended dose  (mg/day)  225  225  250  275  275  300  325  350  350  375  400  400  425   143 The above relationships are calculated from the equation derived from the data, (n~136), daily dose~3·5116 kg + 77·386, which is the slice taken from the multiple regression equation at a plasma phenytoin concentration of6O~mol/I (15 mg/I), ie, the middle of the therapeutic range.
In most patients (8S%) the above recommended dose given, divided per day. will give plasma phenytoin levels in the therapeutic range. In order to obtain a more accurate description of the relationships between body weight, dose of the drug, and the plasma phenytoin the data were subjected to a multiple linear regression analysis as an approximation to the two curvilinear plots mentioned earlier. A plot of this equation in three dimensions is illustrated in diagrammatic form in Figure 3 . The equation can be used to provide an estimate of the phenytoin dose required to give a desired plasma concentration in a patient of any weight, but in order to simplify calculation the values around the middle of the therapeutic range-60 flomolfl (15 mgfl)-relating to weight in kilogrammes are shown in Table 2 . As Phenytoin tablets are available in 25 mg increments, the recommended doses have been rounded to the nearest 25 mg.
An illustration of the effect on the plasma phenytoin of changing the dosage using the equation is shown in Table 3 , where a group with levels outside the therapeutic range show the majority within the range after adjustment of the daily dose. Table 4 shows the proportion of those patients on phenytoin alone who had 'fits' while on treat- Some were thought to be non-compliant, and the clinical desirability of having plasma phenytoin concentrations in the therapeutic range is indicated by the low percentage of those with fits (X'~11·42; P<O·OI). ment or were clinically well and demonstrates the clinical desirability of having blood values within the therapeutic range.
Discussion
Many patients on prolonged administration of phenytoin may be seen relatively infrequently in the outpatients department and could spend long periods on a non-optimal regimen. The group of patients studied here had been taking the drug for periods of from two months to four years and only about 36 % had blood phenytoin in the therapeutic range. The clinical desirability of being in this range is shown here in that far fewer patients have clinical symptoms (Table 4) . When a patient is put on phenytoin it may take up to five days to reach a steady state where monitoring of the blood concentration can be made and the necessary adjustments carried out. If a rational dose can be given from the beginning then the likelihood of achieving the correct therapeutic level may be enhanced. It is suggested in this paper that the rational dosage regimen should take account of the patient's weight, assuming that the volume of distribution of the drug is some fixed function of it. Occasionally this will not be true-in the presence of alcohol? or cirnetidine," for instance, or genetic factors controlling microsomal oxidation."
The actual blood concentration of phenytoin is the resultant of the factors mentioned together with the pharmacokinetic behaviour, and the data used to calculate the multiple regression inherently contain them all. By isolating one easily measurable factor, the patient's weight, it is possible to take a slice out of the whole relationship ( Fig. 3) and, by deciding on a value for phenytoin in the middle of the therapeutic range, it is simple to give the relationship between the weight and the required daily dosage to arrive at this value in the blood. Pippengerprovides a rule of thumb by multiplying the mg/kg/ day by five to arrive at the daily dose for adults, but this value is too high for the overweight or larger members of the population tested in this study, and the simplified regression equation gives 3·5 mgjkg Gray plus 77 mg (Table 2) . This calculated dosage gave, on average, a blood phenytoin of approximately 13 mgjl (SD = 4·2) in a selected group of patients (Table 3) , all of whom had previously been outside the therapeutic range. From the data shown in Table 4 it is evident that being in the range is associated with a lesser percentage frequency of fits than being outside it.
